risedronic acid has been researched along with menatetrenone in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kashima, I; Kawamata, R; Kozai, Y; Matsumoto, Y; Mikuni-Takagaki, Y; Miyagawa, K; Naruse, K; Sakurai, T; Wakao, H | 1 |
| Sato, Y | 1 |
| Hayashida, N; Honda, Y; Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Umeno, K | 1 |
| Furukawa, M; Izumo, N; Kanda, J; Shimakura, T; Takahashi, HE; Wakabayashi, H; Yamamoto, N | 1 |
1 review(s) available for risedronic acid and menatetrenone
| Article | Year |
|---|---|
[Dementia and fracture].
Topics: Accidental Falls; Bone Density; Dementia; Etidronic Acid; Hip Fractures; Humans; Hyperparathyroidism, Secondary; Osteoporosis; Risedronic Acid; Risk; Risk Factors; Sunlight; Vitamin D Deficiency; Vitamin K 2; Vitamin K Deficiency | 2010 |
1 trial(s) available for risedronic acid and menatetrenone
| Article | Year |
|---|---|
The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Hemostatics; Hip Fractures; Humans; Hyperparathyroidism; Male; Osteoporosis; Risedronic Acid; Vitamin D; Vitamin K; Vitamin K 2 | 2011 |
2 other study(ies) available for risedronic acid and menatetrenone
| Article | Year |
|---|---|
Prior treatment with vitamin K(2) significantly improves the efficacy of risedronate.
Topics: Animals; Body Weight; Bone Density Conservation Agents; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Etidronic Acid; Female; Femur; Mice; Mice, Inbred ICR; Osteoporosis; Ovariectomy; Risedronic Acid; Vitamin K 2 | 2009 |
Effects of the combined administration of risedronate and menatetrenone on bone loss induced by tacrolimus in rats.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Drug Therapy, Combination; Femur; Immunosuppressive Agents; Male; Osteogenesis; Rats, Wistar; Risedronic Acid; Tacrolimus; Tibia; Vitamin K 2 | 2020 |